Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Gross Margin (2019 - 2025)

Catalyst Pharmaceuticals' Gross Margin history spans 7 years, with the latest figure at 82.91% for Q4 2025.

  • For Q4 2025, Gross Margin fell 182.0% year-over-year to 82.91%; the TTM value through Dec 2025 reached 85.19%, down 81.0%, while the annual FY2025 figure was 85.19%, 81.0% down from the prior year.
  • Gross Margin reached 82.91% in Q4 2025 per CPRX's latest filing, down from 84.73% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 88.35% in Q1 2023 to a low of 80.82% in Q4 2021.
  • Average Gross Margin over 5 years is 85.41%, with a median of 85.66% recorded in 2022.
  • Peak YoY movement for Gross Margin: crashed -348bps in 2021, then surged 413bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 80.82% in 2021, then rose by 1bps to 81.57% in 2022, then grew by 5bps to 85.7% in 2023, then fell by -1bps to 84.74% in 2024, then dropped by -2bps to 82.91% in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Gross Margin are 82.91% (Q4 2025), 84.73% (Q3 2025), and 85.94% (Q2 2025).